Status:
COMPLETED
Prognostic Value of NLR, TLR, and ALC in Predicting ToF Primary Repair Outcome
Lead Sponsor:
National Cardiovascular Center Harapan Kita Hospital Indonesia
Conditions:
Congenital Heart Disease
Tetralogy of Fallot
Eligibility:
All Genders
Up to 18 years
Brief Summary
Tetralogy of Fallot (ToF) were cyanotic congenital heart disease with chronic hypoxia which increases the risk of exacerbated inflammatory response in ToF primary repair. Various studies have recently...
Detailed Description
This was a retrospective observational study on tetralogy of Fallot (ToF) primary repair in National Cardiovascular Center Harapan Kita between Januari 2020 until December 2022. The preoperative demog...
Eligibility Criteria
Inclusion
- All patients with ToF and any other associated cardiac anomalies, who underwent ToF primary repair and had a complete blood cell count with differential count available preoperatively
Exclusion
- Surgery other than ToF primary repair
- Association with other procedures (except patent ductus arteriosus/PDA ligation, patent foramen ovale/PFO or atrial septal defect/ASD closure, or pulmonary arteries enlargement)
- Preoperative hemodynamic instability
- Suspected or confirmed infection with prior antibiotic administration during the same hospital admission
- Absence of complete blood count with differential count
Key Trial Info
Start Date :
January 1 2020
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
June 30 2023
Estimated Enrollment :
501 Patients enrolled
Trial Details
Trial ID
NCT05976204
Start Date
January 1 2020
End Date
June 30 2023
Last Update
August 8 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
National Cardiovascular Center Harapan Kita Jakarta Indonesia
Jakarta, Indonesia